Biokinetics of In-111-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor

Citation
P. Bernhardt et al., Biokinetics of In-111-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor, NUCL MED BI, 28(1), 2001, pp. 67-73
Citations number
21
Categorie Soggetti
Medical Research Diagnosis & Treatment
Journal title
NUCLEAR MEDICINE AND BIOLOGY
ISSN journal
09698051 → ACNP
Volume
28
Issue
1
Year of publication
2001
Pages
67 - 73
Database
ISI
SICI code
0969-8051(200101)28:1<67:BOIINM>2.0.ZU;2-1
Abstract
The long time biokinetics of the radiolabeled somatostatin analogues In-111 -DTPA-D-Phe(1)-octreotide was studied in nude mice transplanted with the hu man carcinoid tumor, GOT1. The results were compared with those from the pa tient with the original tumor. This patient has been diagnosed and later tr eated with In-111-DTPA-D-Phe(1)-octreotide. The animals received about 2 MB q In-111-DTPA-D-Phe(1)-octreotide (0.1 mug) by injection into a tail vein. The animals were killed 0.5 h-14 d after injection of the radiopharmaceutic al. Tumor tissue and normal tissues were collected and weighed and measured for In-111 activity. The In-111 uptake in the tumor was higher than in all normal tissues except the kidneys, The tumor-to-normal-tissue activity con centration, TNC, increased with time for all normal tissues studied. These data were similar to those observed for the original tumor in the patient. The similar biokinetics for In-111-DTPA-D-Phe(1)-octreotide in the tumor-be aring mice and the patient makes this animal model suitable as a model for evaluation of therapy of somatostatin receptor (sstr) expressing tumors wit h radiolabeled somatostatin analogues. Furthermore, the increase with time of TNC both in mice and the patient indicates that long-lived radionuclides are preferred for therapy with radiolabeled somatostatin analogues. (C) 20 01 Elsevier Science Inc. All rights reserved.